糖尿病黄斑浮腫に対するトリアムシノロンアセトニド硝子体投与の短期治療成績

Short-term outcome of intravitreal injection of triamcinolone acetonide for diabetic macular edema

要約　目的：糖尿病黄斑浮腫（DME）に対するトリアムシノロンアセトニド（マキュエイド^®）硝子体内投与の短期治療成績と副作用の検討をした。対象と方法：DMEに対してマキュエイド^®を単独投与した患者24例30眼（42〜83歳。眼内レンズ挿入眼25眼，汎網膜光凝固術施行24眼）。方法として，マキュエイド^®単独硝子体内投与前，投与後1か月，3か月の視力（logMAR），中心窩網膜厚，眼圧について比較検討した。結果：投与前，投与後1か月，3か月のそれぞれの中心窩網膜厚は486.5±151.48，299.8±103.48，328.4±122.54，視力（logMAR）は0.6±0.24，0.3±0.24，0.3±0.23と有意に改善した（p＜0.05）。眼圧上昇は2例にあったが，点眼でのコントロールが可能であった。白内障の進行はなかった。結論：マキュエイド^®は防腐剤を含まないステロイド製剤としてDMEの治療の選択肢となり，効果の継続が期待できる。

Abstract.　Purpose：To resent a report on short-term outcome of intravitreal injection of triamcinolone acetonide for diabetic macular edema. Case and Method：This study was made on 30 eyes of 24 cases with diabetic macular edema. The series comprised 17 males and 7 females. The age ranged from 42 to 83 years, average 64 years. Only five eyes were phakic. Panretinal photocoagulation had been performed on 24 eyes. Cases were followed up for 3 months after intravitreal injection of triamcinolone. Visual acuity was evaluated as logMAR. Results：Visual acuity averaged 0.6±0.24 before treatment, 0.3±0.24 one month and 0.3±0.23 3 months after treatment. The differences were significant（p＜0.05）. Foveal thickness averaged 486±151.48, 299.8±130.48 and 328.4±122.54 respectively. The differences were significant. Complications, including cataract, were absent throughout. Conclusion：Intravitreal injection was followed by visual acuity and decreased foveal thickness for 3 months in eyes with diabetic macular edema.